SE445217B - Nya mellanprodukter, (legre alkyl)-5.6-diklor-3.4-dihydro-2(1h)-iminokinazolin-3-acetathydrohalider, for framstellning av foreningen 6.7-diklor-1.5-dihydroimidazo /2,1-b/ kinazolin-2(3h)-on med blodplettantiaggregerande - Google Patents

Nya mellanprodukter, (legre alkyl)-5.6-diklor-3.4-dihydro-2(1h)-iminokinazolin-3-acetathydrohalider, for framstellning av foreningen 6.7-diklor-1.5-dihydroimidazo /2,1-b/ kinazolin-2(3h)-on med blodplettantiaggregerande

Info

Publication number
SE445217B
SE445217B SE7903198A SE7903198A SE445217B SE 445217 B SE445217 B SE 445217B SE 7903198 A SE7903198 A SE 7903198A SE 7903198 A SE7903198 A SE 7903198A SE 445217 B SE445217 B SE 445217B
Authority
SE
Sweden
Prior art keywords
dichlorobenzyl
dichloro
dihydro
glycine
amino
Prior art date
Application number
SE7903198A
Other languages
English (en)
Swedish (sv)
Other versions
SE7903198L (sv
Inventor
T A Jenks
Jr W N Beverung
R A Partyka
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of SE7903198L publication Critical patent/SE7903198L/xx
Publication of SE445217B publication Critical patent/SE445217B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE7903198A 1978-04-10 1979-04-10 Nya mellanprodukter, (legre alkyl)-5.6-diklor-3.4-dihydro-2(1h)-iminokinazolin-3-acetathydrohalider, for framstellning av foreningen 6.7-diklor-1.5-dihydroimidazo /2,1-b/ kinazolin-2(3h)-on med blodplettantiaggregerande SE445217B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/894,464 US4146718A (en) 1978-04-10 1978-04-10 Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides

Publications (2)

Publication Number Publication Date
SE7903198L SE7903198L (sv) 1979-10-11
SE445217B true SE445217B (sv) 1986-06-09

Family

ID=25403115

Family Applications (2)

Application Number Title Priority Date Filing Date
SE7903198A SE445217B (sv) 1978-04-10 1979-04-10 Nya mellanprodukter, (legre alkyl)-5.6-diklor-3.4-dihydro-2(1h)-iminokinazolin-3-acetathydrohalider, for framstellning av foreningen 6.7-diklor-1.5-dihydroimidazo /2,1-b/ kinazolin-2(3h)-on med blodplettantiaggregerande
SE8404061A SE454990B (sv) 1978-04-10 1984-08-10 Forbettrat forfarande for framstellning av foreningen 6,7-diklor-1,5-dihydroimidazo/2,1-b/kinazolin-2(3h)-on

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE8404061A SE454990B (sv) 1978-04-10 1984-08-10 Forbettrat forfarande for framstellning av foreningen 6,7-diklor-1,5-dihydroimidazo/2,1-b/kinazolin-2(3h)-on

Country Status (19)

Country Link
US (1) US4146718A (de)
JP (2) JPS54135794A (de)
AU (1) AU527748B2 (de)
BE (1) BE875475A (de)
CA (1) CA1109067A (de)
CH (1) CH639079A5 (de)
DE (1) DE2914494A1 (de)
DK (1) DK156062C (de)
FI (1) FI66616C (de)
FR (1) FR2422649A1 (de)
GB (1) GB2018765B (de)
GR (1) GR72937B (de)
HU (2) HU187562B (de)
IE (1) IE48150B1 (de)
NL (1) NL191182C (de)
SE (2) SE445217B (de)
SU (1) SU1120923A3 (de)
YU (1) YU40554B (de)
ZA (1) ZA791727B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1131631A (en) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
US4818273A (en) * 1983-11-14 1989-04-04 The Dow Chemical Company Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
JPH05271200A (ja) * 1991-05-22 1993-10-19 Egyt Gyogyszervegyeszeti Gyar ６，７−ジクロロ−１，５−ジヒドロ−イミダゾ〔２，１−ｂ〕キナゾリン−２〔３Ｈ〕−オンの製造方法
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
AU3885901A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
DE10301105B4 (de) * 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation
ES2344062T5 (es) * 2003-01-23 2013-04-26 Shire Biopharmaceuticals Holdings Ireland Limited Formulación y procedimientos para el tratamiento de la trombocitopenia
AT412873B (de) * 2004-02-20 2005-08-25 Aop Orphan Pharmaceuticals Ag Verfahren zur herstellung von anagrelid hydrochlorid
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (de) * 2006-03-08 2008-11-19 Braincells, Inc. Neurogenesemodulation durch nootropika
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
MX2008014320A (es) * 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
EP2068872A1 (de) * 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066355A2 (de) * 2006-09-19 2009-06-10 Braincells, Inc. Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese
GB0623749D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CA2675265A1 (en) * 2007-02-06 2008-07-14 Cipla Limited Process for the preparation of ethyl-n-(2, 3-dichloro-6-nitrobenzyl) glycine hydrochloride
CN101463035A (zh) * 2007-12-19 2009-06-24 华生制药私人有限公司 生产盐酸阿那格雷一水合物的改进方法
GB0808951D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808953D0 (en) 2008-05-16 2008-06-25 Shire Llc substituted quinazolines
GB0808944D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201004491D0 (en) 2010-03-18 2010-05-05 Shire Llc Quinazoline analogues
GB201017783D0 (en) 2010-10-21 2010-12-01 Shire Llc Process for the preparation of anagrelide and analogues thereof
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
EP2945948B1 (de) 2013-01-18 2020-04-29 Synthon BV Kristalline form ii von anagrelidhydrochloridmonohydrat
WO2014139572A1 (en) * 2013-03-14 2014-09-18 Synthon Bv Process for making anagrelide
WO2014206484A1 (en) 2013-06-28 2014-12-31 Synthon B.V. Process for making anagrelide
CN106854162A (zh) * 2016-12-13 2017-06-16 浙江海正化工股份有限公司 一种2,3‑二氯‑6‑硝基苯胺及其制备方法
CN107903217B (zh) * 2017-11-16 2021-11-23 湖北省宏源药业科技股份有限公司 一种阿那格雷杂质b的制备方法
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
EP3852732A1 (de) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg-lipide und deren verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
BE794964A (fr) * 1972-02-04 1973-08-02 Bristol Myers Co Nouveaux agents hypotenseurs et procede pour les preparer
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.

Also Published As

Publication number Publication date
FI791125A (fi) 1979-10-11
DK156062C (da) 1989-11-06
AU527748B2 (en) 1983-03-24
FI66616B (fi) 1984-07-31
DE2914494A1 (de) 1979-10-18
BE875475A (fr) 1979-10-10
AU4588979A (en) 1979-10-18
CA1109067A (en) 1981-09-15
DE2914494C2 (de) 1989-07-20
IE48150B1 (en) 1984-10-17
DK144779A (da) 1979-10-11
FR2422649A1 (fr) 1979-11-09
FR2422649B1 (de) 1983-07-29
YU83079A (en) 1983-12-31
NL7902825A (nl) 1979-10-12
NL191182B (nl) 1994-10-03
IE790753L (en) 1979-10-10
HU187562B (en) 1986-01-28
GB2018765B (en) 1982-08-04
HU179424B (en) 1982-10-28
SE454990B (sv) 1988-06-13
SE7903198L (sv) 1979-10-11
US4146718A (en) 1979-03-27
ZA791727B (en) 1980-05-28
SE8404061L (sv) 1984-08-10
GR72937B (de) 1984-01-13
JPH0312066B2 (de) 1991-02-19
FI66616C (fi) 1984-11-12
JPS54135794A (en) 1979-10-22
JPH0233035B2 (de) 1990-07-25
SE8404061D0 (sv) 1984-08-10
NL191182C (nl) 1995-03-01
GB2018765A (en) 1979-10-24
DK156062B (da) 1989-06-19
YU40554B (en) 1986-02-28
JPH0222276A (ja) 1990-01-25
CH639079A5 (de) 1983-10-31
SU1120923A3 (ru) 1984-10-23

Similar Documents

Publication Publication Date Title
SE445217B (sv) Nya mellanprodukter, (legre alkyl)-5.6-diklor-3.4-dihydro-2(1h)-iminokinazolin-3-acetathydrohalider, for framstellning av foreningen 6.7-diklor-1.5-dihydroimidazo /2,1-b/ kinazolin-2(3h)-on med blodplettantiaggregerande
AU2013272007B2 (en) Processes to produce certain 2-(pyridine-3-yl)thiazoles
US9603846B2 (en) Process for the preparation of apixaban
WO2011109932A1 (en) Novel process for the manufacture of 5-halogenated-7-azaindoles
CN102659789B (zh) 一锅法制备替莫唑胺的方法及替莫唑胺的精制方法
US4052394A (en) 2-(dicyanomethylene)-1,3-dithiolo-(4,5-b)pyrazine-5,6-dicarbonitrile
JPH0782268A (ja) ベンゾチアジアゾール誘導体の製法
NO830877L (no) Tricykliske derivater av 5,6-dihydro-11h-dibenzo-(b,e)azepin-6-on med farmakologisk aktivitet og fremgangsmaate for deres fremstilling
SK59995A3 (en) Process for preparing enantiomerically pure 6-£(4-chlorophenyl) (1h-triazol-1,2,4-triazol-1-yl) methyl|-1-methyl-1h-benzotriazole, intermediates for its production and method of its production
CA1137474A (en) Preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1- b]quinazolin-2(3h)-one
US4701528A (en) Intermediates useful in the preparation of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates and process for preparing same
JPH0532672A (ja) 置換６−（３，５，６，７−テトラヒドロピロロ［２．１−ｃ［１．２．４−チアジアゾール−３−イリデンイミノ）−７−フルオロ−２Ｈ−１，４−ベンゾオキサジン−３（４Ｈ）−オンの製造方法およびＮ−（４−フルオロ−２−ヒドロキシフエニル）−２−クロロアセトアミド
Bodtke et al. Synthesis of 5-thioxo-6H-imidazo [1, 2-c] quinazolines and related compounds based on cyclocondensations of 2-isothiocyanatobenzonitrile (ITCB) with α-aminoketones
George et al. Condensed 1, 3-benzothiazines. Facile rearrangement of 3-alkyl-8-nitro-s-triazolo [3, 4-b](1, 3, 4) benzothiadiazepine
CA2661737C (en) Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates
JPH0530835B2 (de)
KR800000431B1 (ko) 3-이속사졸릴 요소 유도체의 제조방법
JPS61200978A (ja) ３−置換アミノ−１，３−チアゾリジン−２，４−ジオン誘導体及びその製造法
JPS6051180A (ja) １，２，４−トリアゾリン−５−オン類の製造方法
US5756729A (en) Process for the manufacture of 8-chloro-6 (2-fluorophenyl)-1 methyl-4H-imidazo 1,5a! 1,4! benzodiazepine (midazolam)
CA2121845A1 (en) Heterocyclic compounds and their preparations and use
KR19990047362A (ko) (-)-3(s)-메틸피리도 벤즈옥사진 중간 유도체의 제조방법
US5792874A (en) Process for the manufacture of 8-chloro-6-(2-flourophenyl)-1-methyl-4H-imidazo 1,5A! 1,4!benzodiazepine (midazolam)
DE3153481C2 (de) Zwischenstufen zur Herstellung herbizid wirksamer 2-(2-Imidazolin-2-yl)-pyridine und -chinoline
US20190248782A1 (en) Method for preparing maraviroc

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7903198-5

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7903198-5

Format of ref document f/p: F